Rigel Pharmaceuticals (FRA:RI2) Cash Flow for Dividends: €0.0 Mil (TTM As of Mar. 2026)


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
76 GF Score
Price €31.86
GF Value €23.38
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Cash Flow for Dividends?

Rigel Pharmaceuticals FRA:RI2 +0.89% 76 Cash Flow for Dividends is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 76/100 and a GF Value™ of €23.38. The stock has 7 warning signs investors should review.

Rigel Pharmaceuticals's cash flow for dividends for the three months ended in Mar. 2026 was €0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Rigel Pharmaceuticals Cash Flow for Dividends Related Terms

Rigel Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Cash Flow for Dividends Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rigel Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:RI2
76GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.0 Mil mean?
Rigel Pharmaceuticals (FRA:RI2) has a Cash Flow for Dividends of €0.0 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Rigel Pharmaceuticals and its competitors.
Is Rigel Pharmaceuticals' Cash Flow for Dividends too high?
Rigel Pharmaceuticals' current Cash Flow for Dividends is €0.0 Mil. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Cash Flow for Dividends compare to CBIO and TRAX?
Rigel Pharmaceuticals' Cash Flow for Dividends of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Cash Flow for Dividends is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Cash Flow for Dividends of €0.0 Mil. The stock's GF Value™ is €23.38, compared to a current price of €31.86 — trading 36.3% above its estimated fair value. The current Cash Flow for Dividends is €0.0 Mil. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Cash Flow for Dividends is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €31.86 is trading 36.3% above its estimated GF Value™ of €23.38.

Key valuation signals for FRA:RI2:

  • Cash Flow for Dividends: €0.0 Mil
  • GF Value™: €23.38 vs. price of €31.86 (36.3% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score

Get the complete analysis for FRA:RI2

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.86
Price
€23.38
GF Value